ASH 2019 | Mosunetuzumab induces CR in B-NHL R/R to CAR-T
Stephen Schuster
• 8 Dec 2019
Stephen Schuster, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses an open-label, multicenter, Phase I/Ib, dose escalation and expansion study of mosunetuzumab in patients with B-cell non-Hodgkin lymphoma (NHL), who are relapsed/refractory to CAR-T therapies or for those a delay in effective therapy prevents this approach (GO29781; NCT02500407). Preliminary data support that mosunetuzumab has favorable tolerability and durable efficacy in heavily pre-treated relapsed or refractory B-cell NHL. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
